World J Gastroenterol. 2011 Aug 28;17(32):3663-4. doi: 10.3748/wjg.v17.i32.3663.
Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modification and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.
非酒精性脂肪性肝炎（NASH）是许多西方国家进行肝移植的一个重要适应证。肥胖和胰岛素抵抗是 NASH 最常见的两个危险因素，可导致肝移植后 NASH 复发。目前尚无 NASH 的获批疗法，治疗方法主要针对危险因素的改善和生活方式的改变。甜菜碱曾用于 NASH 的治疗，但结果不一，在临床试验中与其他药物联合使用可能具有一定前景。
